SCHEMBL1384952

SCHEMBL1384952

Nc1onc2cccc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 16/20 0.74
KIT P10721 8/20 0.74
FLT3 P36888 8/20 0.74
RIPK1 Q13546 2/20 0.63
TEK Q02763 4/20 0.59
EPHB4 P54760 3/20 0.59
CSF1R P07333 3/20 0.59
FLT1 P17948 3/20 0.59
SRC P12931 2/20 0.59
FLT4 P35916 2/20 0.59
ABL1 P00519 2/20 0.59
LCK P06239 2/20 0.59
FYN P06241 2/20 0.59
LYN P07948 2/20 0.59
BLK P51451 2/20 0.59
PDGFRB P09619 3/20 0.58
GSK3A P49840 2/20 0.58
GSK3B P49841 2/20 0.58
EGFR P00533 1/20 0.58
PDGFRA P16234 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4737823 0.89 KDR (0.70) KDRKITFLT3TEKCSF1R
SCHEMBL4736486 0.88 KDR (0.72) KDRKITFLT3RIPK1TEK
SCHEMBL1384286 0.87 KDR (0.73) KDRKITFLT3RIPK1TEK
SCHEMBL4740446 0.87 KDR (0.68) KDRKITFLT3RIPK1TEK
SCHEMBL4739581 0.86 KDR (0.62) KDRKITFLT3RIPK1TEK
SCHEMBL5249583 0.86 KDR (0.73) KDRKITFLT3RIPK1CSF1R
SCHEMBL4736275 0.85 KDR (0.71) KDRKITFLT3CSF1RFLT1
SCHEMBL419559 0.85 KIT (1.00) KDRKITFLT3RIPK1MET
SCHEMBL4738177 0.84 KDR (0.64) KDRKITFLT3RIPK1TEK
SCHEMBL421220 0.83 KDR (0.77) KDRKITFLT3RIPK1TEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4810427-B2 2011-11-09 JP claimed
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed
EP-1638941-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-03-29 EP claimed
WO-2004113304-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-12-29 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP disclosed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO disclosed